AI Bias Analysis
4 models · Takes ~15 seconds
Sarepta Therapeutics’ next crop of medicines for muscular dystrophy appear to be safe and effective in early clinical trials, the company said.
Source
Stat News
Opens original article in a new tab
The FDA approved a new medicine from Denali Therapeutics for Hunter syndrome, a notable decision by the agency after a string of rejections of rare disease drugs.
In this edition of STAT's AI Prognosis: A chat with Qualified Health co-founder and CEO, Justin Norden, as the company raises $125 million.
(MedPage Today) -- The NIH has cut the number of solicited calls for funding, and instead has been directed to increase its spending on "unsolicited" proposals driven by investigators' interests. (Nature) Confidential health data stored in the...
(MedPage Today) -- After adjusting for underreporting of alcohol consumption, the prevalence of alcohol-related liver diseases in the U.S. was found to be higher than has been previously reported, with binge drinking being the strongest risk factor...